/stocks — the workspaceLOADING
All CCEL SEC filings, by type → · Earnings date & implied move · Search inside filings
CCEL is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
Latest report (10-Q, filed 2026-10-09). Three months to 2026-08-31 against 2025-08-31: Revenue $7.8M, down 0.0% from $7.8M; Net income $1.3M, up 69.5% from $749,408. Nine months to 2026-08-31 against 2025-08-31: Operating cash flow $3.6M, down 13.3% from $4.2M. Read it line by line, each linked to its source → · Every report →
CRYO CELL INTERNATIONAL INC (CCEL) is a services-misc health & allied services, nec company. Piotroski F-Score 6/8. 3 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
What’s behind CCEL’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
Nothing on file for CCEL from Nov 3, 2026 to Nov 16, 2026 in these sources: earnings date and filing deadline.
| Event | Result |
|---|---|
| Earnings date | nothing in the window. No date in the window: no regular report cadence in the filings. |
| Filing deadline | nothing in the window. Nothing in the window: the 10-K for the fiscal year ending Nov 30, 2026, due 90 days after it for a non-accelerated filer, falls due Mar 1, 2027, after it. Newest periodic report on file: the 10-Q for the period ending Aug 31, 2026, filed Oct 9, 2026. filing list on EDGAR |
| Ex-dividend date | not covered. Not checked. This attestation does not cover ex-dividend dates. |
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-03 to 2026-11-16, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2017-11-30 vs 2016-11-30. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
| Free cash flow per share | That year | Year before, same report | Change | Report |
|---|---|---|---|---|
| fiscal 2025 | 0.65 USD | 0.44 USD | +48.1% | 10-K filed 2026-02-27 |
| fiscal 2024 | 0.44 USD | 0.25 USD | +76.1% | 10-K filed 2025-02-28 |
| fiscal 2023 | 0.25 USD | -0.42 USD | not a growth rate (a year at or below zero) | 10-K filed 2024-02-28 |
| fiscal 2022 | -0.42 USD | 0.73 USD | not a growth rate (a year at or below zero) | 10-K filed 2023-02-28 |
| fiscal 2021 | 0.73 USD | 1.03 USD | -29.1% | 10-K filed 2022-02-22 |
| fiscal 2020 | 1.03 USD | 0.67 USD | +53.5% | 10-K filed 2021-03-01 |
| fiscal 2019 | 0.67 USD | 0.65 USD | +2.8% | 10-K filed 2020-02-28 |
| fiscal 2018 | 0.65 USD | 0.73 USD | -10.8% | 10-K filed 2019-02-28 |
| fiscal 2017 | 0.73 USD | 0.57 USD | +28.3% | 10-K filed 2018-02-28 |
| fiscal 2016 | 0.57 USD | 0.48 USD | +18.2% | 10-K filed 2017-02-28 |
Concepts read: (us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations - us-gaap:PaymentsToAcquirePropertyPlantAndEquipment) / us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding; (us-gaap:NetCashProvidedByUsedInOperatingActivities - us-gaap:PaymentsToAcquirePropertyPlantAndEquipment) / us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
| Diluted EPS | That year | Year before, same report | Change | Report |
|---|---|---|---|---|
| fiscal 2025 | -0.30 USD | 0.05 USD | not a growth rate (a year at or below zero) | 10-K filed 2026-02-27 |
| fiscal 2024 | 0.05 USD | -1.14 USD | not a growth rate (a year at or below zero) | 10-K filed 2025-02-28 |
| fiscal 2023 | -1.14 USD | 0.33 USD | not a growth rate (a year at or below zero) | 10-K filed 2024-02-28 |
| fiscal 2022 | 0.33 USD | 0.25 USD | +32.0% | 10-K filed 2023-02-28 |
| fiscal 2021 | 0.25 USD | 0.45 USD | -44.4% | 10-K filed 2022-02-22 |
| fiscal 2020 | 0.45 USD | 0.27 USD | +66.7% | 10-K filed 2021-03-01 |
| fiscal 2019 | 0.27 USD | -0.11 USD | not a growth rate (a year at or below zero) | 10-K filed 2020-02-28 |
| fiscal 2018 | -0.11 USD | 0.30 USD | not a growth rate (a year at or below zero) | 10-K filed 2019-02-28 |
| fiscal 2017 | 0.30 USD | -0.16 USD | not a growth rate (a year at or below zero) | 10-K filed 2018-02-28 |
| fiscal 2016 | -0.16 USD | 0.83 USD | not a growth rate (a year at or below zero) | 10-K filed 2017-02-28 |
Concepts read: us-gaap:EarningsPerShareDiluted
Per filed share, as each report states it. Free cash flow per share is operating cash flow less capital expenditure, over the diluted weighted average share count (or net income over diluted EPS where the count is tagged per share class).
Each year’s change comes from one annual report, which states that year and the year before on the same share basis, and the rate compounds those changes; so a split or a restatement between reports cannot bend it. A rate needs a positive figure at both ends of its window. The DCF above grows total free cash flow and divides by today’s share count, so a per-share rate also carries the buybacks or new shares of those years. These are past figures, not a forecast.
Not shown yet: the P/E range CCEL has traded at, which would set the discount rate and terminal assumptions against its own history. It needs a long daily price history we are not yet licensed to display.
Stage-1 growth down the side, discount rate across the top, with terminal growth at 2.5% and 10 years of stage 1. Every cell runs the same two-stage DCF as the card above, so moving a slider moves the grid.
| Growth ↓ Discount → | 7% | 8% | 9% | 10% | 11% |
|---|---|---|---|---|---|
| 4% | 16.74 | 13.64 | 11.49 | 9.92 | 8.72 |
| 6% | 19.68 | 15.94 | 13.37 | 11.48 | 10.05 |
| 8% | 23.13 | 18.64 | 15.55 | 13.30 | 11.58 |
| 10% | 27.15 | 21.78 | 18.09 | 15.41 | 13.37 |
| 12% | 31.85 | 25.45 | 21.05 | 17.85 | 15.43 |
| Growth the close implies | -10.3% | -8.2% | -6.4% | -4.7% | -3.1% |
Outlined: your current pair. Shaded: at or above the last close, 5.35 USD. The heavy line runs between the cells on either side of it.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from CCEL’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as CCEL tagged it: revenue us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on CCEL plus an auto-SWOT, built from CCEL's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate CCEL using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Ask about CCEL’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Has CCEL been issuing shares? Offering history →
No lawmaker has disclosed a trade in CCEL under the STOCK Act.
Closes only, split-adjusted. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
Daily closes from 2024-07-01 through 2026-11-02, 586 sessions, split-adjusted. No direction, pattern, entry, target or overbought label: these are measurements. Filings dated on the move days are in CCEL’s filings; the chart with studies draws every figure.
Written by code from 586 end-of-day bars through 2026-11-02. Written by code from the data on file, not by a model. Information, not investment advice: it describes the security and recommends nothing to anyone.
Projected from CCEL's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentCCEL files or announces.
| Reported | Close-to-close |
|---|---|
| 2024-10-17 | +1.5% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
Volume against its own history: 73% of its last 252 sessions were lighter than the last one, the 2026-11-02 session. End-of-day bars (Databento). Volume detail
Both dividends and buybacks are in use — a mixed return policy. Buybacks flex with cash flow; dividends carry a stronger implicit commitment to maintain.
Every figure is from CCEL’s SEC cash-flow statement. This describes how management deployed cash last period — it is not a grade of that deployment, not a forecast, and not investment advice. Whether reinvesting, paying down debt, or returning cash was the right call depends on the return each earns, which the filings do not settle. Educational information only.
1 of 5 estimators could run on CCEL's filings. A band needs at least 2.
One estimator is a point estimate, not a range, so no band and no valuation label are published for CCEL. Below is everything that was checked, so the refusal can be read rather than taken on trust.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for CCEL, so sector medians could not fill the gaps.
Every refusal recorded for CCEL → · How often we decline, and why →
No tracked institution reported a position in CCEL in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 38 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Group: Services-Misc Health & Allied Services, NEC, the SEC industry code CCEL files under. 1 company in our stored table files under it.
| Metric | CCEL | Group median | 25th to 75th percentile | Where CCEL sits |
|---|---|---|---|---|
| Net marginnet income divided by revenue, same fiscal year | Withheld: 1 company in this SIC group has the figure on file, and a group prints from 6. | |||
| Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year | Withheld: 1 company in this SIC group has the figure on file, and a group prints from 6. | |||
| Return on equitynet income divided by stockholders’ equity at the fiscal year end | Withheld: 0 companies in this SIC group have the figure on file, and a group prints from 6. | |||
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
The score is passed over computable, not passed out of five. If only three tests could be run on CCEL’s filings, the score is out of three and the other two are listed with the reason they were skipped. Scoring a skipped test as a failure would punish a company for how its industry reports, and scoring it as a pass would flatter one.
Labels come from that ratio:
Below three computable tests we publish no label at all and show the individual results instead. A summary drawn from one or two tests is not a summary.
Free cash flow coverage carries the most weight in practice, because dividends are paid in cash and free cash flow is the cash actually available to pay them. The earnings payout ratio is the better-known test but the weaker one — earnings are an accounting figure, dividends are not. Where the two disagree, believe the cash.
Why tests get skipped. A REIT gets no earnings payout ratio: GAAP depreciation on appreciating property understates a REIT’s distributable earnings, which is exactly why the industry reports FFO and why REITs are required to distribute most of their taxable income. Banks and insurers get no leverage test, because deposits are debt and structurally high leverage is what a balance-sheet business is, not a warning sign.
The biggest limitation, stated plainly. The coverage tests read a single fiscal year, and one year of cash flow is far more volatile than a dividend record. A legal settlement, a tax payment or an acquisition can sink coverage in a year that says nothing about the dividend. Where a weak year contradicts a long unbroken record, we say so above rather than letting the harsher number stand alone — but you should still check what happened in that specific year.
The streak is the weakest test here, and it is deliberately listed last. Every dividend that was ever cut had an unbroken streak right up until the year it was cut. A freeze does not break the run — a company that holds its dividend flat through a bad year has not cut it — so raises are counted separately, and a long flat run cannot pass itself off as dividend growth.
Every figure above is from CCEL’s own SEC filings and the arithmetic is stated on this page. This describes what the filings show about the dividend’s coverage — it is not a prediction that the dividend will or will not be cut, not a recommendation, and not investment advice. A covered dividend can still be cut, and a strained one can still be maintained for years. Educational information only.
No open-market Form 4 buys or sells reported for CCEL in the last ~6 months.
2 of the 2 checks that ran found nothing new for CCEL. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Head office: Oldsmar, Florida, United States · the company’s charter and its head office are in different states.
Source: the cover page of CRYO CELL INTERNATIONAL INC’s 10-Q filed 2026-10-09, on EDGAR. Filings checked 2026-11-03. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works